CONTEXT: Hyperinsulinemia is associated with colon carcinoma in the general population. PATIENTS with acromegaly are considered to be at risk for developing colonic lesions and typically have hyperinsulinemia. OBJECTIVE: Our objective was to evaluate the role of fasting insulin levels on the prevalence of colonic adenomatous polyps or adenocarcinoma in acromegaly. DESIGN: This is an analytical, observational, prospective study. PATIENTS: A total of 210 patients (111 women, 99 men, age 20-82 yr) undergoing complete colonoscopy at diagnosis of acromegaly were included in this study. RESULTS: Colonic lesions were found in 81 patients (38.6%), and consisted of hyperplastic polyps in 33 (15.7%), adenomatous polyps in 42 (20.0%), and adenocarcinoma in six patients (2.8%). Polyps were single in 22 cases (27.1%). Fasting insulin levels were significantly lower in patients without lesions (16.0 +/- 7.5 mU/liter) than in patients with hyperplastic polyps (22.4 +/- 8.8 mU/liter; P < 0.01), adenomatous polyps (38.0 +/- 15.9 mU/liter; P < 0.0001), and adenocarcinoma (59.0 +/- 30.6 mU/liter; P < 0.0001). Fasting insulin levels were also lower in patients with hyperplastic polyps than in those with adenomatous polyps (P < 0.01). The odds ratio for harboring colonic adenomas was 14.8 (95% confidence interval 4.4-51.2; P < 0.0001) and 8.6 times higher (95% confidence interval 2.8-29.0; P < 0.0001) in patients with fasting insulin levels in the upper tertile [>/=27.1 mIU/liter (n = 28)] compared with the lower [</=12.1 mIU/liter (n = 40)] and middle tertiles [>12.1 to <27.1 mIU/liter (n = 74)], respectively. CONCLUSION: An increase in fasting insulin levels is associated with an 8.6- to 14.8-fold increased risk of presenting with colonic adenomas in acromegaly.
CONTEXT: Hyperinsulinemia is associated with colon carcinoma in the general population. PATIENTS with acromegaly are considered to be at risk for developing colonic lesions and typically have hyperinsulinemia. OBJECTIVE: Our objective was to evaluate the role of fasting insulin levels on the prevalence of colonic adenomatous polyps or adenocarcinoma in acromegaly. DESIGN: This is an analytical, observational, prospective study. PATIENTS: A total of 210 patients (111 women, 99 men, age 20-82 yr) undergoing complete colonoscopy at diagnosis of acromegaly were included in this study. RESULTS:Colonic lesions were found in 81 patients (38.6%), and consisted of hyperplastic polyps in 33 (15.7%), adenomatous polyps in 42 (20.0%), and adenocarcinoma in six patients (2.8%). Polyps were single in 22 cases (27.1%). Fasting insulin levels were significantly lower in patients without lesions (16.0 +/- 7.5 mU/liter) than in patients with hyperplastic polyps (22.4 +/- 8.8 mU/liter; P < 0.01), adenomatous polyps (38.0 +/- 15.9 mU/liter; P < 0.0001), and adenocarcinoma (59.0 +/- 30.6 mU/liter; P < 0.0001). Fasting insulin levels were also lower in patients with hyperplastic polyps than in those with adenomatous polyps (P < 0.01). The odds ratio for harboring colonic adenomas was 14.8 (95% confidence interval 4.4-51.2; P < 0.0001) and 8.6 times higher (95% confidence interval 2.8-29.0; P < 0.0001) in patients with fasting insulin levels in the upper tertile [>/=27.1 mIU/liter (n = 28)] compared with the lower [</=12.1 mIU/liter (n = 40)] and middle tertiles [>12.1 to <27.1 mIU/liter (n = 74)], respectively. CONCLUSION: An increase in fasting insulin levels is associated with an 8.6- to 14.8-fold increased risk of presenting with colonic adenomas in acromegaly.
Authors: Maria Luisa Torre; Giuseppina T Russo; Marta Ragonese; Annalisa Giandalia; Ernesto De Menis; Giorgio Arnaldi; Angela Alibrandi; Carmelo Buda; Giovanni Romanello; Elisabetta L Romeo; Domenico Cucinotta; Francesco Trimarchi; Salvatore Cannavo Journal: Pituitary Date: 2014-06 Impact factor: 4.107
Authors: F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni Journal: J Endocrinol Invest Date: 2010-07-01 Impact factor: 4.256
Authors: F Bogazzi; M Lombardi; I Scattina; C Urbani; E Marciano; A Costa; P Pepe; G Rossi; E Martino Journal: J Endocrinol Invest Date: 2010-02-24 Impact factor: 4.256
Authors: M Parolin; F Dassie; L Russo; S Mazzocut; M Ferrata; E De Carlo; R Mioni; F Fallo; R Vettor; C Martini; P Maffei Journal: Pituitary Date: 2018-02 Impact factor: 4.107
Authors: M Lombardi; I Scattina; C Sardella; C Urbani; E Marciano; S Signori; L Ruocco; G Pellegrini; E Martino; F Bogazzi Journal: J Endocrinol Invest Date: 2013-01-14 Impact factor: 4.256
Authors: C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio Journal: J Endocrinol Invest Date: 2009-04-29 Impact factor: 4.256